DIRS.INFO The most relevant business & tech news

☆ Novavax stock jumps 50% as Sanofi deal kicks off turning point for struggling vaccine maker
▼ + stars: | 2024-05-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Shares of Novavax jumped as much as 50% on Monday as Wall Street cheered the company's new multibillion-dollar deal with French drugmaker Sanofi that sparked a dramatic turnaround for the struggling vaccine maker. Novavax's stock almost doubled on Friday after it announced the licensing agreement with Sanofi. Under the agreement, Sanofi will take a less than 5% stake in Novavax. Sanofi, one of the world's largest vaccine makers, will co-market Novavax's Covid vaccine in most countries starting in 2025. The deal also allows Sanofi to use Novavax's Covid shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products.

Persons: Novavax, Sanofi, John Jacobs Organizations: French, Sanofi, Novavax, CNBC Locations: Novavax

☆ Novavax signs multibillion-dollar deal with Sanofi to commercialize Covid vaccine, develop combination shots
▼ + stars: | 2024-05-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company's Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. Part of the deal allows Sanofi to use Novavax's Covid shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products. Novavax is also entitled to royalty payments on Sanofi's sales of its Covid vaccine and combination shots targeting coronavirus and the flu. Under the deal, Sanofi will also take a less than 5% stake in Novavax.

Persons: Novavax, Sanofi, John Jacobs, Jacobs Organizations: Dutch Health Service Organization, French, CNBC, Health, Pfizer, Moderna, Sanofi Locations: The Hague, Netherlands, Novavax

☆ Novavax to settle dispute over canceled Covid vaccine purchase agreement
▼ + stars: | 2024-02-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a canceled Covid vaccine purchase agreement. In 2022, Novavax terminated a purchase agreement with Geneva-based Gavi. Under the settlement, Novavax has paid an initial $75 million to Gavi and will make deferred payments of $80 million each year through Dec. 31. Analysts had previously told CNBC that Novavax could "be in trouble" if the arbitration forced it to pay the full $700 million to Gavi in 2023.

Persons: Novavax, Gavi, bode, David Marlow Organizations: Dutch Health Service Organization, CNBC Locations: The Hague, Netherlands, Geneva, Novavax

☆ Novavax's updated Covid vaccine can still catch up to Pfizer, Moderna shots this fall
▼ + stars: | 2023-10-07 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +6 min

The biotech company is banking on sales of its updated Covid vaccine — its only commercially available product — and a broad cost-cutting push to help it stay afloat. Novavax's shot fends off the virus with protein-based technology, a decades-old method used in routine vaccinations against hepatitis B and shingles. The federal government shifted Covid vaccine distribution and coverage to the private market for the first time this fall. A sign advertises COVID-19 (coronavirus) vaccine shots at a Walgreens Pharmacy in Somerville, Massachusetts, August 14, 2023. Some pharmacies, like Walgreens , also appear to be resolving supply disruptions, which left many stores without any new Covid shots for patients to receive.

Persons: Patrick Van Katwijk, Novavax, aren't, Mayank Mamtani, fends, Silvia Taylor, Taylor, Novavax's, Mamtani, Hannah Beier, Jefferies, Roger Song, Brian Snyder, Biden Organizations: Dutch Health Service Organization, Getty, Pfizer, Moderna, Drug Administration, Riley Securities, CNBC, Covid, FDA, Bloomberg, Insurance, Walgreens, Reuters Locations: The Hague, Netherlands, U.S, Schwenksville , Pennsylvania, Somerville , Massachusetts

A vial labelled "Novavax COVID-19 Vaccine" is seen in this illustration taken January 16, 2022. The Maryland-based company, whose COVID vaccine is its lone marketed product, has adopted cost-cutting measures and is counting on commercial sales of its updated shot to help it stay afloat. The CDC's Advisory Committee on Immunization Practices (ACIP) will not meet again to discuss the Novavax shot, a spokesperson said. Novavax's original COVID shot received U.S. authorization in July 2022, long after Pfizer and Moderna vaccines were in use. All three of the updated shots target the XBB.1.5 variant of the coronavirus.

Persons: Dado Ruvic, BioNTech, COVID, John Jacobs, Jacobs, Sriparna Roy, Bill Berkrot Organizations: REUTERS, U.S . Food, Drug Administration, U.S . Centers for Disease Control, Prevention, Pfizer Inc, Moderna, FDA, Pfizer, Moderna's, Thomson Locations: U.S, Maryland, Bengaluru

☆ FDA authorizes updated Novavax Covid vaccine as Pfizer, Moderna shots roll out in U.S.
▼ + stars: | 2023-10-03 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

"In the coming days, individuals in the U.S. can go to major pharmacies, physicians' offices, clinics and various government entities to receive an updated Novavax vaccine." Last month, the FDA and CDC greenlit XBB.1.5 shots from Pfizer and Moderna for all Americans ages six months and older. The end of that declaration means all three manufacturers will sell their updated shots directly to health-care providers and vie for commercial market share. That includes the Biden administration's Bridge Access Program, which will provide Covid vaccines at no cost to underinsured and uninsured people. It's unclear how many Americans will actually roll up their sleeves and take the new vaccines from Novavax, Pfizer and Moderna.

Persons: Novavax, John Jacobs, fends, Demetre Daskalakis, Biden, it's, Eris, Megan Wallace Organizations: Drug Administration, Pfizer, Moderna, Centers for Disease Control, Covid, FDA, CDC, EG, Biden Locations: U.S, Novavax

A nurse fills a syringe with malaria vaccine before administering it to an infant at the Lumumba Sub-County hospital in Kisumu, Kenya, July 1, 2022. REUTERS/Baz Ratner/File photo Acquire Licensing RightsGENEVA, Oct 2 (Reuters) - The World Health Organization (WHO) recommended on Monday the use of a second malaria vaccine to curb the life-threatening disease spread to humans by some mosquitoes. recommended the broad use of the world's first malaria vaccine called RTS,S," WHO chief Tedros Adhanom Ghebreyesus told a briefing in Geneva. "Today, it gives me great pleasure to announce that WHO is recommending a second vaccine called R21/Matrix-M to prevent malaria in children at risk of the disease." "GSK has always recognised the need for a second malaria vaccine, but it is increasingly evident that RTS,S, the first ever malaria vaccine and the first ever vaccine against a human parasite, set a strong benchmark," GSK said in a statement.

Persons: Baz Ratner, Tedros Adhanom Ghebreyesus, Tedros, Poonawalla, Takeda, Hanna Nohynek, Gabrielle Tétrault, Farber, Leroy Leo, Gareth Jones, Mark Potter Organizations: Lumumba, REUTERS, Rights, World Health Organization, WHO, Britain's University of Oxford, UNICEF, Serum Institute of India, Reuters, GSK plc, United Nations, GSK, Takeda Pharmaceuticals, Thomson Locations: Kisumu, Kenya, Geneva, Ghana, Malawi, Bengaluru

☆ Europe to decide on Novavax's COVID vaccine in October
▼ + stars: | 2023-09-21 | by ( ) www.reuters.com time to read: +1 min

Four vials with the "Nuvaxovid" COVID-19 vaccine from Novavax are pictured in Saabruecken, Germany, February 26, 2022. REUTERS/Frank Simon/File photo Acquire Licensing RightsSept 21 (Reuters) - The European Medicines Agency (EMA) expects to decide on the use of Novavax's (NVAX.O) updated COVID-19 vaccine in October, its director Emer Cooke said on Thursday. The agency had started the evaluation process for the protein-based shot on Aug. 24, Cooke said at a press conference. EU regulators recently gave the green light for an updated COVID-19 vaccine from Pfizer (PFE.N) and its German partner BioNTech (22UAy.DE), which targets the XBB.1.5 variant of Omicron. Moderna's (MRNA.O) updated shot is also on track to win approval.

Persons: Frank Simon, Emer Cooke, Cooke, BioNTech, Novavax, Bhanvi, Michael Erman, Saumyadeb Chakrabarty Organizations: REUTERS, European Medicines Agency, Pfizer, U.S . Food, Drug Administration, FDA, Moderna, Thomson Locations: Saabruecken, Germany, United States, Bengaluru, New York

☆ New Covid boosters could reach Americans as soon as Thursday – here's what you need to know
▼ + stars: | 2023-09-13 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +9 min

Brian Cassella | Tribune News Service | Getty ImagesA new round of Covid vaccines is finally here in the U.S. Meanwhile, the FDA is still reviewing a third updated vaccine from Novavax for people ages 12 and up. Here's everything you need to know about the updated Covid vaccines, from where to find them, whether you can get them for free and when to get them. The agency's website outlines more specific guidelines for staying up to date on Covid vaccines, which differ depending on age group and risk level. Kroger Americans will soon be able to use the federal website vaccines.gov to find other locations offering the updated Covid shots, according to a CDC spokesperson.

Persons: Brian Cassella, Covid, Biden, Megan Wallace, they've, Brian Snyder, vaccines.gov, Evelyn Twentyman, Will, Moderna's, Twentyman, Taison Bell, Bell, CDC's Wallace, Wallace Organizations: Pfizer, Tribune, Service, U.S, The, Disease Control, Moderna, Food and Drug Administration, CDC, FDA, Walgreens, CNBC, WALGREENS, CVS Albertsons, Kroger, Manufacturers, CVS, University of Virginia Health, Younger Locations: Chatham , Illinois, U.S, Covid, Somerville , Massachusetts

Most Americans should get an updated COVID-19 vaccine, health officials said Tuesday. Here is what you need to know about the new COVID-19 shots:WHO SHOULD GET THE UPDATED VACCINE? The agency's panel of outside exerts recommended the updated COVID-19 shots by a vote of 13-1. But federal officials said the new COVID-19 shots still will be free to most Americans through private insurance, Medicare or Medicaid. Similar to how flu shots are updated each year, the FDA gave COVID-19 vaccine makers a new recipe for this fall.

Persons: they’ve, ”, Camille Kotton, haven’t Organizations: Centers for Disease Control, CDC, TED, Drug Administration, Pfizer, Moderna, FDA, Massachusetts General Hospital, Associated Press Health, Science Department, Howard Hughes Medical Institute’s Science, Educational Media Group, AP Locations: U.S, Massachusetts, Novavax

☆ US FDA authorizes Pfizer-BioNTech and Moderna's updated COVID shots
▼ + stars: | 2023-09-11 | by ( ) www.reuters.com time to read: +2 min

[1/3] Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. A third shot, made by Novavax (NVAX.O), is still under review by the FDA. But obviously that requires that FDA have decided the data supports it," said Jesse Goodman, a professor at Georgetown and former FDA chief scientist. Moderna and Pfizer, which is partnered with German biotech firm BioNTech SE (22UAy.DE), said the updated vaccines were expected to be available the United States in the coming days. An endorsement by CDC Director Mandy Cohen, expected shortly, should clear the way for the new shots.

Persons: Andrew Kelly, Novavax, Jesse Goodman, —, Mandy Cohen, Cohen, Sriparna Roy, Mariam Sunny, Michael Erman, Shinjini Organizations: Food and Drug Administration, FDA, REUTERS, Pfizer, Moderna, U.S . Food, Drug Administration, for Disease Control, Prevention, Georgetown, EG, CDC, Thomson Locations: White Oak , Maryland, U.S, United States, Bengaluru, New York

☆ FDA approves updated Covid vaccines from Pfizer and Moderna as hospitalizations rise
▼ + stars: | 2023-09-11 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The Food and Drug Administration on Monday approved updated Covid vaccines from Pfizer and Moderna , putting the shots on track to reach Americans within days as U.S. hospitalizations from the virus rise. The updated vaccines from Pfizer and Moderna won't be available to Americans just yet. The Biden administration said in August that it expects new single-strain vaccines from Pfizer, Moderna and Novavax targeting XBB.1.5 to be available to the public in mid-September. The upcoming arrival of updated vaccines offers some reassurance to Americans as the nation sees an increase in Covid cases and hospitalizations. Bourla and Moderna CEO Stéphane Bancel, in a separate statement, urged Americans to receive their updated Covid shot during the same appointment as their annual flu shot.

Persons: Biden, Pfizer's, Albert Bourla, Stéphane Bancel, hospitalizations Organizations: Pfizer, BioNTech, Peabody Institute Library, Drug Administration, Moderna, FDA, CDC, Covid, EG Locations: Peabody , Massachusetts, U.S

☆ Novavax shares surge after drugmaker says new Covid vaccine was effective against Eris variant
▼ + stars: | 2023-08-22 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Shares of Novavax jumped more than 13% on Tuesday after the biotech company said its new Covid vaccine generated a broad immune response against the now-dominant Eris variant and another fast-spreading strain of the virus in small animal trials. But the trial results suggest that the shot may still be effective against newer Covid variants gaining a greater foothold in the U.S. That includes Eris and XBB.1.16.6, both of which are also descendants of omicron. "We have a lot of confidence in our updated Covid vaccine and are working diligently with global regulatory bodies to ensure our protein-based vaccine is available this fall," Filip Dubovsky, Novavax's president of research and development, said in a release. The World Health Organization designated Eris a "variant of interest," meaning it will be monitored for mutations that could make it more severe. XBB.1.16.6 is also beginning to surge, accounting for 8% of all cases nationwide as of Saturday, the CDC said.

Persons: Novavax, Filip Dubovsky Organizations: Pfizer, Moderna, U.S . Food, Drug Administration, EG, Centers for Disease Control, World Health Organization, CDC Locations: U.S, hospitalizations

☆ Novavax shares jump after Covid vaccine maker posts surprise quarterly profit
▼ + stars: | 2023-08-08 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

Shares of Novavax jumped as much as 20% in premarket trading Tuesday after the Covid vaccine maker reported a surprise second-quarter profit. Here's what Novavax reported compared with Wall Street's expectations, based on a survey of analysts by Refinitiv. That compares with a net loss of $510.5 million, or $6.53 per share, reported during the same quarter last year. But Jacobs noted that the adjustment reflects part of a cash settlement the Canadian government agreed to pay for forfeiting Covid vaccine doses that were previously scheduled for delivery. The company reported R&D expenses of $258 million and SG&A expenses of $162 million last year.

Persons: Novavax, John Jacobs, Jacobs, We're, it's Organizations: Refinitiv, CNBC, and Drug Administration Locations: Krakow, Poland

☆ Novavax posts quarterly profit on COVID vaccine sales
▼ + stars: | 2023-08-08 | by ( ) www.reuters.com time to read: +2 min

Companies Novavax Inc FollowAstraZeneca PLC FollowBioNTech SE Follow Show more companiesAug 8 (Reuters) - Novavax (NVAX.O) reported a second-quarter profit on Tuesday, helped by strong revenue from its COVID-19 vaccines, but still trimmed its annual forecast for sales of the shot. As part of the agreement, Novavax will issue 6.5 million shares to SK Bioscience at $13 per share. Following the agreements, Novavax now owes SK Bioscience $65 million in cash. The company reported revenue of $424 million, compared with analysts' estimates of $240 million, according to Refinitiv IBES data. Novavax lowered the sales forecast for its COVID-19 vaccines to between $1.3 billion and $1.5 billion this year, compared with a previous outlook of $1.4 billion to $1.6 billion.

Persons: Novavax, Leroy Leo, Michael Erman, Varun H, Maju Samuel, Shounak Organizations: AstraZeneca, SK Bioscience, South Korean, South, Thomson Locations: KS, South Korean, United States, Bengaluru, New York

☆ Novavax stock spikes 20% after company snags $350 million from Canada for unused Covid shots
▼ + stars: | 2023-07-10 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

It's unclear how many doses of Novavax's jab – its only commercially available product after 35 years – went unused. Under the amended agreement, Novavax will also provide Canada with fewer doses of its vaccine on a revised delivery schedule. In May, Novavax adopted a more positive outlook and announced a sweeping cost-cutting plan alongside its first-quarter earnings report. Novavax's stock price jumped around 30% on that news, but Wall Street hasn't entirely bought into the recovery plan: The company's stock price is still down roughly 15% since the start of the year after shedding more than 90% of its value in 2022. Novavax still faces a number of challenges ahead, including competing with Pfizer and Moderna in the commercial Covid vaccine market and a pending $700 million arbitration over a canceled vaccine purchase agreement.

Persons: –, Novavax Organizations: SEC, Canadian, Securities and Exchange Commission, Pfizer, Moderna Locations: Maryland, Canada

☆ Pfizer, Moderna and Novavax gear up for fall Covid vaccine rollout with an important head start
▼ + stars: | 2023-06-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

But facing pressure to deliver new shots by the fall, Pfizer, Moderna and Novavax began development on versions of their vaccines targeting XBB.1.5 months before the FDA's decision. That doesn't include Johnson & Johnson , a once-leading Covid vaccine developer. Moderna expects a minimum of $5 billion in revenue from its Covid vaccine, its only available product. The cash-strapped company won U.S. approval for its Covid vaccine under emergency use just last year due to regulatory and manufacturing delays. The company hopes to rake in $1.06 billion to $1.24 billion in sales of its Covid vaccine this year.

Persons: Novavax, Dr, Melinda Wharton, Johnson Organizations: Chicago Department of Public Health, Southwest Senior Center, The U.S . Food, Pfizer, Moderna, FDA, Centers for Disease Control, National Center, Manufacturers, U.S, Moderna's Locations: COVID, Chicago , Illinois, The U.S, Novavax, U.S

☆ Covid vaccine maker Novavax sees a pathway to survival – but it won’t be easy
▼ + stars: | 2023-06-14 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +10 min

Jakub Porzycki | NurPhoto | Getty ImagesNovavax has a clear message for Wall Street: The cash-strapped Covid vaccine maker sees a pathway to survival. The 36-year-old company will continue to rely on its protein-based Covid vaccine – its only commercially available product – for most of its revenue this year. Once the U.S. government's supply of free Covid vaccines runs out, all three companies will sell updated shots directly to health-care providers. A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. But Taylor emphasized that the plan will help Novavax refocus on its top priority: delivering an updated vaccine in the coming months.

Persons: Jakub Porzycki, Novavax, Covid, Cowen, Brendan Smith, John Jacobs, Smith, that's, Silvia Taylor, Taylor, Jefferies, Roger Song, Patrick Van Katwijk, Mayank Mamtani, let's, Mamtani, Let's, Song, Ding Genhou Organizations: NurPhoto, Getty, Pfizer, Moderna, CNBC, Food and Drug Administration, World Health Organization, FDA, Dutch Health Service Organization, Riley Securities, U.S, Centers for Disease Control, CDC, Reuters, Visual China Locations: Krakow, Poland, Maryland, U.S, The Hague, Netherlands, Moderna, Geneva, Hohhot, Inner Mongolia Autonomous Region, China

☆ Cramer's Lightning Round: Novavax is a no-go
▼ + stars: | 2023-05-31 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

Stock Chart Icon Stock chart icon Jazz Pharmaceuticals' year-to-date stock performance. Stock Chart Icon Stock chart icon ON Semiconductor's year-to-date stock performance. Stock Chart Icon Stock chart icon Novavax's year-to-date stock performance. Stock Chart Icon Stock chart icon Golar LNG's year-to-date stock performance. Stock Chart Icon Stock chart icon Tyson Foods' year-to-date stock performance.

Persons: it's, I'd, You've, Golar, Tyson Organizations: Jazz Pharmaceuticals, Investing, ON, Golar, New Fortress Energy, Tyson Foods Locations: Moderna

Novavax, whose COVID vaccine is its lone marketed product after 35 years in business, is relying on launching an updated COVID shot this fall to match circulating strains and cost cuts to improve its prospects. Novavax said $800 million of that was from "locked-in" overseas purchase contracts for the COVID shot that it has committed to ship this year. Novavax is working to produce an update version of its protein-based vaccine in time for the fall COVID-19 booster season. Novavax expects the cost cuts to reduce its annual research and commercial expenses by 20% to 25% from last year. Data from a mid-stage trial in adults aged 50 to 80 years showed that the combination shot produced an immune response comparable to its protein-based COVID vaccine and already approved influenza shots, Novavax said.

☆ Novavax lays off 25% of workforce, releases 2023 outlook
▼ + stars: | 2023-05-09 | by ( ) www.reuters.com time to read: +1 min

May 9 (Reuters) - Novavax (NVAX.O) said on Tuesday it will reduce its global workforce by 25% as the cash-strapped biotech pushes forward with its plans to slash expenses and navigate tepid demand for its COVID-19 vaccines. Separately, Novavax said its COVID/flu combination shot was safe and well-tolerated in a mid-stage study, sending shares of the company up 9% before the bell. For the first quarter, it reported a net loss of $293.9 million, compared with a year-ago profit of $203.4 million. The biotech expects the cost-cut plans to help reduce its annual research and commercial expenses by 20% to 25% from last year. The company had $637 million in cash and equivalents at the end of the quarter, compared with $1.3 billion as of Dec. 31.

☆ Novavax surges more than 25% after company unveils job cuts, positive vaccine data
▼ + stars: | 2023-05-09 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. The company's Covid vaccine is its lone marketed product after 35 years in business. The company reported R&D expenses of $258 million and SG&A expenses of $162 million last year. The company raced against Pfizer and Moderna to develop the first Covid vaccine early in the pandemic. Novavax's shot is the first Covid vaccine to use protein technology, a decades-old method for fighting viruses used in routine vaccinations against hepatitis B and shingles.

The company — which has its COVID-19 vaccine as the only marketed product after 35 years in business — on Tuesday flagged significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi. Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. Novavax faces near-term risks as protein-based vaccines take longer to produce than mRNA-based competitors, Novavax CEO John Jacobs has said. "While there is the potential for a substantial booster market ... we don't expect Novavax to be a major player in the booster opportunity." As of last close, Novavax's U.S.-listed shares were down 97% from their February 2021 record high of $331.68.

☆ Jim Cramer's top 10 things to watch in the stock market Wednesday: China, stocks, retail
▼ + stars: | 2023-03-01 | by ( Jim Cramer | ) www.cnbc.com time to read: +4 min

(See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

The stock had dropped 26.2% to $6.83 around 8:55 ET (13:55 GMT), while its Frankfurt-listed shares slumped more than 27%. The company - whose COVID vaccine is its only marketed product after 35 years in business - on Tuesday flagged significant uncertainty around its 2023 revenue, funding from the U.S. government, and pending arbitration with global vaccine alliance Gavi. Syringes with needles are seen in front of a displayed Novavax logo in this illustration taken, November 27, 2021. Novavax faces near-term risks as protein-based vaccines take longer to produce than mRNA-based competitors, Novavax CEO John Jacobs has said. As of last close, Novavax's U.S.-listed shares are down 97% from their February 2021 record high of $331.68.

Search resuls for: "Novavax's"

25 mentions found